| abstract |
Use of galectin-2 or of a nucleic acid coding for galectin-2 or ofnits complementary strand, or of a nucleic acid hybridizing to suchncoding nucleic acid or its complementary strand, for the manufacture ofna medicament for the treatment of a patient having a disease withnimpaired apoptosis of T-cells, macrophages and/or antigen-presentingncells, e.g. autoimmune diseases or malignant T-cell diseases. |